Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Loftfield, Erikka ^a   O'Brien, Thomas R ^a   Pfeiffer, Ruth M ^a   Howell, Charles D ^b   Horst, Ron ^c   Prokunina Olsson, Ludmila ^a   Weinstein, Stephanie J ^a   Albanes, Demetrius ^a   Morgan, Timothy R ^d   Freedman, Neal D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Heartland Assays   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; PEGINTERFERON ALPHA; RIBAVIRIN; VITAMIN D; ALPHA INTERFERON; ANTIVIRUS AGENT; VITAMIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; EUROPEAN AMERICAN; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; VIROLOGIC RESPONSE; VITAMIN BLOOD LEVEL; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME; VITAMIN D; VITAMINS;

EID: 84994476399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0166036     Document Type: Article

References (51)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17(2):107-15. doi: 10.1111/j.1469-0691.2010.03432.x PMID: 21091831
2. WHO. Hepatitis C 2002 [October 7, 2015]. Available from: http://www.who.int/csr/disease/hepatitis/ whocdscsrlyo2003/en/index4.html.
3. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008; 14(11):1652-6. doi: 10.3748/wjg.14.1652 PMID: 18350595
4. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ. Viral hepatocarcinogenesis: From infection to cancer. Liver Int. 2008; 28(2):175-88. doi: 10.1111/j.1478-3231.2007.01652.x PMID: 18251977
5. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0 PMID: 23245604
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13):975-82. doi: 10.1056/ NEJMoa020047 PMID: 12324553
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65 PMID: 11583749
8. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341(8):556-62. doi: 10.1056/NEJM199908193410802 PMID: 10451460
9. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004; 39(6):1702-8. doi: 10.1002/hep. 20212 PMID: 15185312
10. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012; 54(1):96-104. doi: 10.1093/cid/cir774 PMID: 22156853
11. Hoofnagle JH, Sherker AH. Therapy for hepatitis C-the costs of success. N Engl J Med. 2014; 370 (16):1552-3. doi: 10.1056/NEJMe1401508 PMID: 24725236
12. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol. 2013; 11(11):1503-10. doi: 10.1016/j.cgh.2013.05. 014 PMID: 23707354
13. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013; 57(4):1325-32. doi: 10.1002/hep.26246 PMID: 23315914
14. Rao VB, Johari N, du Cros P, Messina J, Ford N, Cooke GS. Hepatitis C seroprevalence and HIV coinfection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15 (7):819-24. doi: 10.1016/S1473-3099(15)00006-7 PMID: 25957078
15. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4):1333-42. doi: 10.1002/hep.26141 PMID: 23172780
16. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko F, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015; 64:1824-33. doi: 10. 1136/gutjnl-2015-310421 PMID: 26449729
17. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype1. Gastroenterology. 2006; 131(2):470-7. doi: 10.1053/j.gastro.2006.06.008 PMID: 16890601
18. O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, et al. Comparison of Functional Variants in IFNL4 and IFNL3 for Association with Hepatitis C Virus Clearance. J Hepatol. 2015. doi: 10.1016/j.jhep.2015.06.035 PMID: 26186989
19. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013; 45(2):164-71. doi: 10.1038/ng.2521 PMID: 23291588
20. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the IFNL4-DeltaG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis. 2014; 209(3):350-4. doi: 10.1093/infdis/jit433 PMID: 23956438
21. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015; 373(8):705-13. doi: 10.1056/ NEJMoa1501315 PMID: 26196665
22. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol. 2011; 17(47):5184-90. doi: 10.3748/wjg.v17.i47.5184 PMID: 22215943
23. Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int. 2011; 24(1):43-50. doi: 10.1111/j.1432-2277.2010.01141.x PMID: 20649944
24. Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol. 2011; 54(5):887-93. doi: 10.1016/j.jhep.2010.08.036 PMID: 21145801
25. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008; 8(9):685-98. doi: 10.1038/nri2378 PMID: 19172691
26. Christakos S, Dhawan P, Benn B, Porta A, Hediger M, Oh GT, et al. Vitamin D: molecular mechanism of action. Ann N Y Acad Sci. 2007; 1116:340-8. doi: 10.1196/annals.1402.070 PMID: 18083936
27. Matsumura T, Kato T, Sugiyama N, Tasaka-Fujita M, Murayama A, Masaki T, et al. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology. 2012; 56(4):1231-9. doi: 10.1002/hep.25763 PMID: 22487892
28. Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, et al. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology. 2011; 54(5):1570-9. doi: 10.1002/hep.24575 PMID: 21793032
29. Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, et al. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother. 2007; 51(6):2016-27. doi: 10.1128/AAC.01426-06 PMID: 17420205
30. Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and metaanalysis. J Hepatol. 2014; 61(6):1247-52. doi: 10.1016/j.jhep.2014.08.004 PMID: 25135863
31. Garcia-Alvarez M, Pineda-Tenor D, Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Resino S. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis. Hepatology. 2014; 60(5):1541-50. doi: 10.1002/hep.27281 PMID: 24975775
32. Ross AC, Taylor CL, Yaktine AL, DelValle HB. Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine, 2011.
33. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004; 25(5):472-92. doi: 10.1016/j.cct.2004.08.003 PMID: 15465617
34. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008; 359(23):2429-41. doi: 10.1056/NEJMoa0707615 PMID: 19052125
35. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004; 126(4):1015-23; discussion 947 PMID: 15057741
36. Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol. 2004; 42(1):421-5 doi: 10.1128/JCM.42. 1.421-425.2004 PMID: 14715796
37. Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE, et al. Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients With Chronic Hepatitis C. Gastroenterology. 2011; 140(7):1961-9. doi: 10.1053/j.gastro.2011.02.061 PMID: 21376050
38. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4):1147-71. doi: 10.1002/hep.20119 PMID: 15057920
39. Gallicchio L, Helzlsouer KJ, Chow WH, Freedman DM, Hankinson SE, Hartge P, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172(1):10-20. doi: 10.1093/aje/kwq116 PMID: 20562188
40. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem. 2009; 42(15):1549-56. doi: 10.1016/j.clinbiochem.2009.07.013 PMID: 19631201
41. Gibbons JD. Median Test, Brown-Mood. Encyclopedia of Statistical Sciences: John Wiley & Sons, Inc.; 2004.
42. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011; 96(1):53-8. doi: 10.1210/jc.2010-2704 PMID: 21118827
43. Raghunathan TE, Lepkowski JM, Hoewyk JV, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodology. 2001; 27.1:85-95.
44. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002; 21(11):1539-58. doi: 10.1002/sim.1186 PMID: 12111919
45. Kitson MT, Sarrazin C, Toniutto P, Roberts SK. Relationship between vitamin D status and response to hepatitis C virus therapy. Hepatology. 2015. doi: 10.1002/hep.27797 PMID: 25808060
46. Bitetto D, Bortolotti N, Falleti E, Vescovo S, Fabris C, Fattovich G, et al. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. Hepatology. 2013; 57(3):925-33. doi: 10.1002/hep.26186 PMID: 23213086
47. Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S, et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology. 2012; 56(5):1641-50. doi: 10.1002/hep.25848 PMID: 22610885
48. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology. 2011; 53(4):1118-26. doi: 10.1002/hep.24201 PMID: 21480318
49. Pineda-Tenor D, Garcia-Alvarez M, Jimenez-Sousa MA, Fernandez-Rodriguez A, Resino S. Reply: To PMID 24975775. Hepatology. 2015; 62(5):1643. doi: 10.1002/hep.27796 PMID: 25807876
50. Weintraub SJ, Fleckenstein JF, Marion TN, Madey MA, Mahmoudi TM, Schechtman KB. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. Am J Clin Nutr. 2012; 96 (5):1025-31. doi: 10.3945/ajcn.112.039974 PMID: 23015322
51. Kitson MT, Dore GJ, George J, Button P, McCaughan GW, Crawford DH, et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol. 2013; 58(3):467-72. doi: 10.1016/j.jhep.2012.11.017 PMID: 23183524